Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report

Abstract Dolutegravir (DTG), an integrase strand transfer inhibitor is currently the recommended first and second line anti-retroviral therapy (ART) anchor agent by the World Health Organization due to its favorable side effect profile, high efficacy and genetic barrier to resistance. Despite its ve...

Full description

Bibliographic Details
Main Authors: Frank Mulindwa, Barbara Castelnuovo, Nele Brusselaers, Robert Bollinger, George Yendewa, Willington Amutuhaire, Claudine Mukashaka, Jean-Marc Schwarz
Format: Article
Language:English
Published: BMC 2023-10-01
Series:BMC Infectious Diseases
Subjects:
HIV
Integrase inhibitors
Dolutegravir
Accelerated hyperglycemia
Type 2 Diabetes Mellitus
Online Access:https://doi.org/10.1186/s12879-023-08712-z

Internet

https://doi.org/10.1186/s12879-023-08712-z

Similar Items